# Cancer drug trials have changed; value assessments must too

> How clinical trials for cancer medicines have evolved, and why regulators need to account for that shift when assessing their worth.
- Title: Cancer drug trials have changed; value assessments must too
- Summary: How clinical trials for cancer medicines have evolved, and why regulators need to account for that shift when assessing their worth. Cancer medicine trials…
- Keywords: cancer medicines, clinical trials, value assessment, drug regulation, gilead sciences, politics, world, Cancer, drug, trials, changed, value
- Source: POLITICO — https://politico.eu/sponsored-content/the-value-assessment-of-cancer-medicines-must-account-for-how-trials-have-changed
- Published: 2026-10-21T08:52:53+00:00
- Read time: 1 min
- Topics: cancer medicines, clinical trials, value assessment, drug regulation, gilead sciences, politics, world
## Cancer trials have changed shape
Clinical trials for cancer medicines have evolved significantly over time. How these trials are designed and run today differs from historical approaches to testing.
## Value assessments lag behind
Regulators assess the value of cancer drugs using methods that may not reflect how modern trials work. Current assessment approaches were built on older trial designs.
## Methods need updating
Value assessment frameworks must evolve to account for how cancer medicine trials have changed. Regulators should align their evaluation methods with current trial practices.
## Key takeaway

Cancer medicine trials have changed significantly, requiring value assessment methods to adapt to reflect how modern trials differ from past approaches.